Mewburn Ellis is proud to work with some of the world’s most globally significant pharmaceuticals, including established giants and rising stars.
The pharmaceuticals sector continues to thrive, with sales of $583 billion in 2023 alone.
As the world moves on from COVID-19, the pharmaceuticals landscape has begun to return to the pre-pandemic norm. Sales of COVID-19 treatments have dropped, with Pfizer and BioNTech’s Comirnaty™, which last year topped the bestselling list, now falling out of the top 5.
Mewburn Ellis has longstanding experience working with some of the most globally significant drugs and therapies. We are proud to have worked on 26 of the top 100 bestselling pharmaceuticals in 2023, including 29% of the top 50 by aggregate sales.
Rising stars in oncology
We are delighted to see oncology drugs on which we have worked enter the top 200 bestselling pharmaceuticals list, including Genentech’s Polivy™, Roche’s Phesgo™, and BeiGene’s Brukinsa™. Mewburn Ellis’ pharma specialists have considerable experience working on some of the world’s most promising cancer therapies.
Monoclonal antibody specialists
Mewburn Ellis is proud to have worked on Vabysmo™, Genentech’s new monoclonal antibody treatment for degenerative eye conditions. Having only gained medical approval in the US and Europe in 2022, the drug has quickly shot up to the top 60 highest selling pharmaceuticals.
Vabysmo™ joins a list of established blockbuster monoclonal antibodies which Mewburn Ellis have helped advise on and secure patent protection for, including Humira™, Herceptin™, Avastin™, Rituxan™, among others. See here for more information about our experience in the antibody and ADC space.
Women’s Health
It is very encouraging to see birth control treatments Mirena™ and Nexplanon™ on the list of top selling drugs. Mewburn Ellis is passionate about women’s health and our colleagues, such as our Women’s Champion and colleague Fran Salisbury, have worked closely on patents and applications which have huge potential to change women’s lives.
This latest report on the world’s bestselling pharmaceuticals demonstrates Mewburn Ellis’ continuing position as one of the best-placed firms to handle the intellectual property rights of some of the most globally-prominent drugs and biologics.
David is a trainee patent attorney working in the fields of chemistry and materials. His areas of expertise include inorganic and organic synthesis, advanced inorganic materials, luminescent materials, gas storage and separation technologies, two-dimensional materials, including graphene, and synthesis and characterisation of crystalline materials.
Email: david.brooks@mewburn.com
